JP2019514863A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019514863A5 JP2019514863A5 JP2018553226A JP2018553226A JP2019514863A5 JP 2019514863 A5 JP2019514863 A5 JP 2019514863A5 JP 2018553226 A JP2018553226 A JP 2018553226A JP 2018553226 A JP2018553226 A JP 2018553226A JP 2019514863 A5 JP2019514863 A5 JP 2019514863A5
- Authority
- JP
- Japan
- Prior art keywords
- solid form
- acceptable salt
- pharmaceutically acceptable
- cancer
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662326156P | 2016-04-22 | 2016-04-22 | |
| US62/326,156 | 2016-04-22 | ||
| PCT/EP2017/059511 WO2017182625A1 (en) | 2016-04-22 | 2017-04-21 | Macrocyclic mcl1 inhibitors for treating cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019514863A JP2019514863A (ja) | 2019-06-06 |
| JP2019514863A5 true JP2019514863A5 (OSRAM) | 2020-05-21 |
| JP6894449B2 JP6894449B2 (ja) | 2021-06-30 |
Family
ID=58664658
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018553226A Active JP6894449B2 (ja) | 2016-04-22 | 2017-04-21 | 癌を治療するためのマクロ環状ｍｃｌ１阻害剤 |
Country Status (37)
Families Citing this family (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2018009408A (es) | 2016-02-04 | 2018-11-09 | Univ Johns Hopkins | Rapaglutinas, nuevos inhibidores de transportadores de glucosa (glut) y uso de los mismos. |
| CN108697701B (zh) | 2016-02-04 | 2021-10-26 | 约翰霍普金斯大学 | 平衡型核苷转运蛋白1的抑制剂Rapadocin及其用途 |
| US11066416B2 (en) | 2016-02-04 | 2021-07-20 | The Johns Hopkins University | Rapafucin derivative compounds and methods of use thereof |
| CN109071566B (zh) | 2016-04-22 | 2021-08-31 | 阿斯利康(瑞典)有限公司 | 用于治疗癌症的大环mcl-1抑制剂 |
| CN109715632B (zh) | 2016-05-19 | 2021-10-26 | 拜尔公开股份有限公司 | 大环吲哚衍生物 |
| TWI781996B (zh) * | 2017-03-31 | 2022-11-01 | 瑞典商阿斯特捷利康公司 | 合成ｍｃｌ-１抑制劑之方法 |
| TW201904976A (zh) * | 2017-03-31 | 2019-02-01 | 瑞典商阿斯特捷利康公司 | Ｍｃｌ-１抑制劑及其使用方法 |
| SG11202001182QA (en) | 2017-08-15 | 2020-03-30 | Abbvie Inc | Macrocyclic mcl-1 inhibitors and methods of use |
| AU2018317836A1 (en) * | 2017-08-15 | 2020-03-19 | AbbVie Deutschland GmbH & Co. KG | Macrocyclic MCL-1 inhibitors and methods of use |
| WO2019096914A1 (en) * | 2017-11-17 | 2019-05-23 | Bayer Aktiengesellschaft | Macrocyclic chlorine substituted indole derivatives |
| WO2019096907A1 (en) * | 2017-11-17 | 2019-05-23 | Bayer Aktiengesellschaft | Aryl annulated macrocyclic indole derivatives |
| EP3710456B1 (en) | 2017-11-17 | 2022-09-21 | The Broad Institute, Inc. | Macrocyclic indole derivatives |
| US11478451B1 (en) | 2017-11-17 | 2022-10-25 | Bayer Aktiengesellschaft | Macrocyclic chlorine substituted indole derivatives |
| UY37971A (es) * | 2017-11-17 | 2019-06-28 | Bayer Ag | Derivados de indol macrocíclicos sustituidos |
| EP3710449B1 (en) | 2017-11-17 | 2022-07-06 | The Broad Institute, Inc. | Macrocyclic fluorine substituted indole derivatives as mcl-1 inhibitors, for use in the treatment of cancer |
| TW202014184A (zh) * | 2018-04-30 | 2020-04-16 | 瑞典商阿斯特捷利康公司 | 用於治療癌症之組合 |
| US20220041623A1 (en) * | 2018-09-30 | 2022-02-10 | Jiangsu Hengrui Medicine Co., Ltd. | Indole macrocyclic derivative, preparation method thereof and application thereof in medicine |
| TWI810397B (zh) | 2018-11-14 | 2023-08-01 | 瑞典商阿斯特捷利康公司 | 治療癌症之方法 |
| CN111205309B (zh) * | 2018-11-21 | 2023-04-07 | 江苏恒瑞医药股份有限公司 | 吲哚类大环衍生物、其制备方法及其在医药上的应用 |
| US11691989B2 (en) | 2018-11-22 | 2023-07-04 | Ascentage Pharma (Suzhou) Co., Ltd. | Macrocyclic indoles as Mcl-1 inhibitors |
| TWI760685B (zh) * | 2019-01-23 | 2022-04-11 | 大陸商蘇州亞盛藥業有限公司 | 作為mcl-1抑制劑的大環稠合的吡唑 |
| MX2021010321A (es) * | 2019-03-08 | 2021-11-17 | Zeno Man Inc | Compuestos macrociclicos. |
| CN113574058B (zh) * | 2019-04-30 | 2024-04-16 | 江苏恒瑞医药股份有限公司 | 吲哚类大环衍生物、其制备方法及其在医药上的应用 |
| CN114127059B (zh) | 2019-05-10 | 2024-09-24 | 詹森生物科技公司 | 大环螯合剂及其使用方法 |
| CN114127079A (zh) | 2019-05-17 | 2022-03-01 | 布罗德研究所有限公司 | 制备大环吲哚的方法 |
| UY38700A (es) | 2019-05-20 | 2020-12-31 | Novartis Ag | Conjugados de anticuerpo-fármaco inhibidores de mcl-1 y sus métodos de uso |
| US20220306653A1 (en) * | 2019-06-21 | 2022-09-29 | Janssen Pharmaceutica Nv | Macrocyclic inhibitors of mcl-1 |
| US20240067660A1 (en) | 2019-07-09 | 2024-02-29 | Janssen Pharmaceutica Nv | Macrocyclic spirocycle derivatives as mcl-1 inhibitors |
| US20220372014A1 (en) * | 2019-10-01 | 2022-11-24 | The Johns Hopkins University | Neuroprotective compounds and methods of use thereof |
| WO2021092053A1 (en) * | 2019-11-08 | 2021-05-14 | Unity Biotechnology, Inc. | Mcl-1 inhibitor macrocycle compounds for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer |
| WO2021092061A1 (en) * | 2019-11-08 | 2021-05-14 | Unity Biotechnology, Inc. | Combination treatment for senescence-associated diseases |
| KR20220103984A (ko) * | 2019-11-21 | 2022-07-25 | 얀센 파마슈티카 엔.브이. | Mcl-1 억제제로서의 거대환식 인돌 유도체 |
| MX2022006180A (es) * | 2019-11-21 | 2022-06-14 | Janssen Pharmaceutica Nv | Derivados macrociclicos de sulfonilo como inhibidores de mcl-1. |
| AU2020409006A1 (en) * | 2019-12-18 | 2022-06-30 | Zeno Management, Inc. | Macrocyclic compounds |
| AU2021222332A1 (en) | 2020-02-21 | 2022-10-20 | Janssen Pharmaceutica Nv | Macrocyclic indole derivatives as inhibitors of MCL-1 |
| CN115335384B (zh) * | 2020-03-30 | 2024-10-22 | 江苏恒瑞医药股份有限公司 | 一种吲哚类大环衍生物的结晶形式及其制备方法 |
| CN115605486A (zh) * | 2020-05-29 | 2023-01-13 | 詹森药业有限公司（Be） | 作为mcl-1抑制剂的大环7-吡唑-5-基-吲哚衍生物 |
| BR112022025631A2 (pt) | 2020-06-19 | 2023-01-17 | Janssen Pharmaceutica Nv | Derivados de 4-(pirazol-5-il)-indol macrocíclico n-ligados como inibidores de mcl-1 |
| WO2021255257A1 (en) | 2020-06-19 | 2021-12-23 | Janssen Pharmaceutica Nv | N-linked macrocyclic 7-(pyrazol-5-yl)-indole derivatives as inhibitors of mcl-1 |
| JP2023532592A (ja) | 2020-07-08 | 2023-07-28 | ヤンセン ファーマシューティカ エヌ．ベー． | Ｍｃｌ－１の阻害剤としての大環状エーテル含有インドール誘導体 |
| WO2022032284A1 (en) * | 2020-08-07 | 2022-02-10 | Zeno Management, Inc. | Macrocyclic compounds |
| US20240042051A1 (en) | 2020-11-24 | 2024-02-08 | Francesca Rocchetti | Mcl-1 inhibitor antibody-drug conjugates and methods of use |
| CA3200758A1 (en) | 2020-12-17 | 2022-06-23 | Janssen Pharmaceutica Nv | Branched macrocyclic 4-(pyrazol-5-yl)-indole derivatives as inhibitors of mcl-1 |
| CN116848126A (zh) | 2021-02-12 | 2023-10-03 | 詹森药业有限公司 | 大环1,3-桥联的6-氯-7-吡唑-4-基-1h-吲哚-2-羧酸酯和6-氯-7-嘧啶-5-基-1h-吲哚-2-羧酸酯衍生物作为mcl-1抑制剂用于治疗癌症 |
| WO2022251247A1 (en) * | 2021-05-28 | 2022-12-01 | Zeno Management, Inc. | Macrocyclic compounds |
| AU2022291381B2 (en) | 2021-06-11 | 2025-04-24 | Gilead Sciences, Inc. | Combination mcl-1 inhibitors with anti-cancer agents |
| EP4351657A1 (en) | 2021-06-11 | 2024-04-17 | Gilead Sciences, Inc. | Combination mcl-1 inhibitors with anti-body drug conjugates |
| CN115490708B (zh) * | 2021-06-18 | 2025-01-24 | 苏州亚盛药业有限公司 | 磺酰胺类大环衍生物及其制备方法和用途 |
| WO2023057484A1 (en) | 2021-10-06 | 2023-04-13 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for predicting and improving the efficacy of mcl-1 inhibitor therapy |
| CR20240553A (es) | 2022-05-20 | 2025-05-02 | Servier Lab | Conjugados de anticuerpo-fármaco de compuestos antineoplásicos y métodos de uso de los mismos |
| WO2025111450A1 (en) | 2023-11-22 | 2025-05-30 | Les Laboratoires Servier | Anti-cd74 antibody-drug conjugates and methods of use thereof |
| WO2025111431A1 (en) | 2023-11-22 | 2025-05-30 | Les Laboratoires Servier | Anti-cd7 antibody-drug conjugates and methods of use thereof |
| WO2025126157A1 (en) | 2023-12-15 | 2025-06-19 | Advesya | Anti-il-1rap binding domains and antibody-drug conjugates thereof |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101511074B1 (ko) * | 2007-04-16 | 2015-04-13 | 애브비 인코포레이티드 | 7-치환된 인돌 Ｍｃｌ-1 억제제 |
| DK2134685T3 (en) | 2007-04-16 | 2015-12-07 | Abbvie Inc | 7-unsubstituted indole derivatives as MCL-1 inhibitors |
| PT2379580E (pt) * | 2008-12-22 | 2014-01-20 | Cubist Pharm Inc | Novos agentes antibacterianos para o tratamento de infecções por bactérias gram positivas |
| CN102822163B (zh) * | 2009-12-23 | 2016-01-20 | 艾恩伍德医药品股份有限公司 | Crth2调节剂 |
| PT2710018T (pt) * | 2011-05-19 | 2022-03-01 | Fundacion Del Sector Publico Estatal Centro Nac De Investigaciones Oncologicas Carlos Iii F S P Cnio | Compostos macrocíclicos como inibidores de proteína quinases |
| WO2014047427A2 (en) | 2012-09-21 | 2014-03-27 | Vanderbilt University | Substituted benzofuran, benzothiophene and indole mcl-1 inhibitors |
| US10005728B2 (en) | 2013-08-28 | 2018-06-26 | Vanderbilt University | Substituted indole Mcl-1 inhibitors |
| ES2654242T3 (es) * | 2014-02-12 | 2018-02-12 | Viiv Healthcare (No.5) Limited | Macrociclos de benzotiazol como inhibidores de la réplica del virus de la inmunodeficiencia humana |
| CN106456602B (zh) | 2014-03-27 | 2020-11-24 | 范德比尔特大学 | 取代的吲哚mcl-1抑制剂 |
| CU24399B1 (es) * | 2014-04-11 | 2019-04-04 | Bayer Pharma AG | Nuevos compuestos macrocíclicos en calidad de inhibidores de cdk9, un proceso para su preparación y los compuestos intermediarios útiles en la preparación de estos compuestos |
| US9949965B2 (en) | 2014-10-17 | 2018-04-24 | Vanderbilt University | Tricyclic indole Mcl-1 inhibitors and uses thereof |
| CN109071566B (zh) | 2016-04-22 | 2021-08-31 | 阿斯利康(瑞典)有限公司 | 用于治疗癌症的大环mcl-1抑制剂 |
-
2017
- 2017-04-21 CN CN201780022366.0A patent/CN109071566B/zh active Active
- 2017-04-21 JP JP2018553226A patent/JP6894449B2/ja active Active
- 2017-04-21 TN TNP/2018/000319A patent/TN2018000319A1/en unknown
- 2017-04-21 BR BR112018070677-9A patent/BR112018070677B1/pt active IP Right Grant
- 2017-04-21 ES ES17720720T patent/ES2791319T3/es active Active
- 2017-04-21 PL PL17720720T patent/PL3445767T3/pl unknown
- 2017-04-21 CO CONC2018/0008759A patent/CO2018008759A2/es unknown
- 2017-04-21 KR KR1020187033540A patent/KR102388208B1/ko active Active
- 2017-04-21 SM SM20200249T patent/SMT202000249T1/it unknown
- 2017-04-21 US US15/493,210 patent/US9840518B2/en active Active
- 2017-04-21 MA MA44721A patent/MA44721B1/fr unknown
- 2017-04-21 AU AU2017252222A patent/AU2017252222B2/en active Active
- 2017-04-21 EP EP17720720.6A patent/EP3445767B1/en active Active
- 2017-04-21 TW TW106113380A patent/TWI742074B/zh active
- 2017-04-21 ME MEP-2020-99A patent/ME03729B/me unknown
- 2017-04-21 MX MX2018012711A patent/MX386103B/es unknown
- 2017-04-21 AR ARP170101026A patent/AR108301A1/es active IP Right Grant
- 2017-04-21 CR CR20180499A patent/CR20180499A/es unknown
- 2017-04-21 SI SI201730246T patent/SI3445767T1/sl unknown
- 2017-04-21 EA EA201892300A patent/EA036551B1/ru not_active IP Right Cessation
- 2017-04-21 PE PE2018001558A patent/PE20181803A1/es unknown
- 2017-04-21 PT PT177207206T patent/PT3445767T/pt unknown
- 2017-04-21 DK DK17720720.6T patent/DK3445767T3/da active
- 2017-04-21 LT LTEP17720720.6T patent/LT3445767T/lt unknown
- 2017-04-21 SG SG11201805838UA patent/SG11201805838UA/en unknown
- 2017-04-21 HU HUE17720720A patent/HUE049591T2/hu unknown
- 2017-04-21 WO PCT/EP2017/059511 patent/WO2017182625A1/en not_active Ceased
- 2017-04-21 RS RS20200549A patent/RS60257B1/sr unknown
- 2017-04-21 HR HRP20200673TT patent/HRP20200673T1/hr unknown
- 2017-10-23 US US15/790,660 patent/US10196404B2/en active Active
-
2018
- 2018-08-23 CL CL2018002410A patent/CL2018002410A1/es unknown
- 2018-09-12 SV SV2018005742A patent/SV2018005742A/es unknown
- 2018-09-25 NI NI201800093A patent/NI201800093A/es unknown
- 2018-10-05 DO DO2018000222A patent/DOP2018000222A/es unknown
- 2018-10-09 IL IL262237A patent/IL262237B/en unknown
- 2018-10-18 PH PH12018502227A patent/PH12018502227A1/en unknown
- 2018-11-19 ZA ZA2018/07766A patent/ZA201807766B/en unknown
- 2018-12-18 US US16/223,538 patent/US10889594B2/en active Active
-
2020
- 2020-05-14 CY CY20201100443T patent/CY1123186T1/el unknown
- 2020-12-04 US US17/111,896 patent/US11472816B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019514863A5 (OSRAM) | ||
| HRP20200673T1 (hr) | Makrociklički inhibitori mcl1 za liječenje raka | |
| ES2988336T3 (es) | Un agente antineoplásico 1-((4-(4-fluoro-2-metil-1H-indol-5-iloxi)-6-metoxiquinolin-7-iloxi)metil)ciclopropanamina, su forma cristalina y sus sales | |
| JP2020521754A5 (OSRAM) | ||
| JP5366968B2 (ja) | Ｄｎａ中のｇ−四重鎖領域と相互作用するナフタレンジイミド化合物 | |
| JP2010539237A5 (OSRAM) | ||
| CR20210626A (es) | Compuestos para el tratamiento de enfermedades y trastornos asociados con braf | |
| JP2020515574A5 (OSRAM) | ||
| JP2019528276A5 (OSRAM) | ||
| JP2020536091A5 (OSRAM) | ||
| EP3173412B1 (en) | 2,4-disubstituted 7h-pyrrolo[2,3-d]pyrimidine derivative, preparation method and medicinal use thereof | |
| WO2016105528A3 (en) | Inhibitors of cyclin-dependent kinase 7 (cdk7) | |
| ES2911040T3 (es) | Nuevos derivados de heteroaril amida como inhibidores selectivos de histona deacetilasa 1 y 2 (HDAC1/2) | |
| WO2016160617A3 (en) | Inhibitors of cyclin-dependent kinases | |
| JP2013512956A5 (OSRAM) | ||
| JP2021530565A5 (OSRAM) | ||
| JP2013512263A5 (OSRAM) | ||
| JP2017509586A5 (OSRAM) | ||
| JP2017511311A5 (OSRAM) | ||
| JP2014524476A5 (OSRAM) | ||
| JP2008535902A5 (OSRAM) | ||
| JP2011527666A5 (OSRAM) | ||
| JP2019514955A5 (OSRAM) | ||
| JP2019534865A5 (OSRAM) | ||
| JP2018522925A5 (OSRAM) |